X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1335) 1335
oncology (1299) 1299
female (1039) 1039
chemotherapy (778) 778
aged (713) 713
middle aged (712) 712
index medicus (643) 643
antineoplastic combined chemotherapy protocols - therapeutic use (642) 642
adult (570) 570
first-line therapy (564) 564
breast neoplasms - drug therapy (528) 528
treatment outcome (495) 495
male (468) 468
cancer (399) 399
first-line chemotherapy (364) 364
first-line treatment (361) 361
breast cancer (336) 336
antineoplastic combined chemotherapy protocols - adverse effects (318) 318
first-line (303) 303
breast neoplasms - pathology (276) 276
postmenopausal women (275) 275
care and treatment (261) 261
paclitaxel (257) 257
neoplasm metastasis (249) 249
aged, 80 and over (246) 246
disease-free survival (244) 244
cisplatin (239) 239
neoplasm staging (228) 228
phase-iii (221) 221
lung neoplasms - drug therapy (219) 219
metastasis (219) 219
antineoplastic agents - therapeutic use (218) 218
trial (211) 211
survival (199) 199
docetaxel (197) 197
pharmacology & pharmacy (197) 197
phase-ii trial (197) 197
combination (194) 194
medicine & public health (192) 192
therapy (191) 191
tamoxifen (190) 190
randomized-trial (189) 189
carcinoma (185) 185
prognosis (184) 184
carcinoma, non-small-cell lung - drug therapy (181) 181
drug administration schedule (178) 178
survival analysis (173) 173
fluorouracil - administration & dosage (172) 172
deoxycytidine - analogs & derivatives (171) 171
fluorouracil (163) 163
carboplatin (161) 161
colorectal neoplasms - drug therapy (161) 161
hematology, oncology and palliative medicine (158) 158
oxaliplatin (157) 157
double-blind (154) 154
metastatic breast cancer (154) 154
anastrozole (153) 153
antineoplastic combined chemotherapy protocols - administration & dosage (147) 147
survival rate (147) 147
bevacizumab (146) 146
clinical trials (143) 143
drug therapy (143) 143
gemcitabine (143) 143
deoxycytidine - administration & dosage (141) 141
vinorelbine (138) 138
capecitabine (137) 137
aromatase inhibitors (136) 136
multicenter (135) 135
antineoplastic agents, hormonal - therapeutic use (133) 133
efficacy (133) 133
endocrine therapy (131) 131
research (130) 130
5-fluorouracil (128) 128
paclitaxel - administration & dosage (128) 128
phase-iii trial (128) 128
clinical trials as topic (126) 126
colorectal cancer (126) 126
disease progression (126) 126
vinblastine - analogs & derivatives (126) 126
randomized trial (124) 124
irinotecan (121) 121
randomized controlled trials as topic (121) 121
analysis (120) 120
open-label (119) 119
chemotherapy, adjuvant (116) 116
cisplatin - administration & dosage (114) 114
vinblastine - administration & dosage (114) 114
megestrol-acetate (110) 110
lung cancer, non-small cell (109) 109
leucovorin (108) 108
retrospective studies (108) 108
postmenopause (107) 107
letrozole (106) 106
respiratory system (106) 106
colorectal neoplasms - pathology (103) 103
follow-up studies (102) 102
lung neoplasms - pathology (101) 101
tamoxifen - therapeutic use (101) 101
antineoplastic agents (99) 99
first line (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1785) 1785
French (40) 40
German (29) 29
Chinese (14) 14
Russian (11) 11
Polish (6) 6
Hungarian (1) 1
Japanese (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 95, pp. 93 - 101
For hormone receptor–positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines... 
First-line treatment | Aromatase inhibitor-sensitive | Hormone receptor–positive HER2-negative metastatic breast cancer | Care and treatment | Cancer patients | Chemotherapy | Breast cancer | Metastasis | Hormones | Epidemiology | Cancer | Life Sciences | Human health and pathology
Journal Article
Pancreas, ISSN 0885-3177, 12/2014, Volume 44, Issue 2, pp. 181 - 189
Objective: The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior... 
Mammalian target of rapamycin inhibition | Chemotherapy | First-line therapy | Everolimus | SURVIVAL | first-line therapy | ISLET-CELL CARCINOMA | BEVACIZUMAB | DOXORUBICIN | GUIDELINES | FLUOROURACIL | chemotherapy | mammalian target of rapamycin inhibition | ENDOCRINE CARCINOMAS | TEMOZOLOMIDE | STREPTOZOCIN | everolimus | THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | United States | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Patient Selection | Pancreatic Neoplasms - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Everolimus - adverse effects | Aged, 80 and over | Adult | Everolimus - therapeutic use | Female | Pancreatic Neoplasms - mortality | Neuroendocrine Tumors - pathology | Double-Blind Method | Pancreatic Neoplasms - pathology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Neuroendocrine Tumors - mortality | Neuroendocrine Tumors - drug therapy | Aged | AE - adverse event | RADIANT - RAD001 in Advanced Neuroendocrine Tumors | PFS - progression-free survival | HR - hazard ratio | CI - confidence interval | NET - neuroendocrine tumors | RECIST - Response Evaluation Criteria in Solid Tumors | SSA - somatostatin analogue | Original | WHO - World Health Organization | pNET - pancreatic neuroendocrine tumors
Journal Article
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 08/2014, Volume 25, Issue 8, pp. 1475 - 1484
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2015, Volume 26, Issue 5, pp. 888 - 894
Background: The first-line combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and platinum-based doublet chemotherapy... 
EGFR mutation | First-line | Chemotherapy | EGFR-TKI | Combination | Non-small cell lung cancer | non-small cell lung cancer | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | OPEN-LABEL | chemotherapy | MAINTENANCE THERAPY | TRIAL | CISPLATIN | ONCOLOGY | first-line | DOUBLE-BLIND | JAPANESE PATIENTS | ERLOTINIB | combination | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Pemetrexed - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Index Medicus
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2016, Volume 18, Issue 1, pp. 34 - 42.e2
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2019, Volume 84, Issue 6, pp. 1349 - 1357
Journal Article
by Bai, L and Wang, F and Li, ZZ and Ren, C and Zhang, DS and Zhao, Q and Lu, YX and Wang, DS and Ju, HQ and Qiu, MZ and Wang, ZQ and Wang, FH and Xu, RH
MEDICINE, ISSN 0025-7974, 12/2016, Volume 95, Issue 51
The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the... 
TARGETED THERAPY | peritoneal metastasis | PERITONEAL CARCINOMATOSIS | cetuximab | MALIGNANT ASCITES | OVARIAN-CANCER | TRIAL | MEDICINE, GENERAL & INTERNAL | MUTATION STATUS | K-RAS | RANDOMIZED PHASE-III | bevacizumab | Chinese population | metastatic colorectal cancer | POOLED ANALYSIS | first-line treatment | ENDOTHELIAL GROWTH-FACTOR
Journal Article